Seattle biotech startup Curi Bio, which allows the screening of recent medicine utilizing cells and 3D tissue fashions derived from human cells, introduced $10 million in new funding.
Curi Bio’s clients embrace massive biopharmaceutical and biotech corporations such Novo Nordisk, Eli Lilly, Astrazeneca, Pfizer, Boehringer Ingelheim, UCB, Novartis and others. Its Collection B spherical was led by Seoul-based DreamCIS, which helps biopharma R&D by intensive analysis providers.
“We’re thrilled to associate with DreamCIS, who shares our conviction that drug discovery urgently wants extra human-relevant knowledge on the preclinical stage,” stated Michael Cho, Curi Bio’s chief technique officer, in a assertion. “The overwhelming majority of recent medicine fail in human medical trials as a result of preclinical animal and 2D cell fashions have did not be good predictors of human outcomes.”
Curi Bio’s platform integrates bioengineered tissues created from induced pluripotent stem cells (iPSCs) with knowledge assortment and evaluation. The extra funding will expedite its improvement of recent platforms for cardiac, skeletal muscle, metabolic, easy muscle and neuromuscular ailments, the corporate stated.
The Seattle space is a hub of life science and biotech corporations, together with quite a few efforts centered on AI-assisted analysis. Researchers have emphasised the necessity to take a look at computer-generated drug candidates within the lab to confirm their capabilities and impacts.
“Curi Bio’s distinctive integration of cells, techniques, and knowledge is a paradigm shift for preclinical drug discovery,” stated Jeounghee Yoo, CEO of DreamCIS. “We have been extremely impressed by the corporate’s progressive platforms and their capacity to generate useful knowledge from 3D human tissues at scale.”
Curi Bio has raised $20 million from traders and $12 million from federal grants.
The corporate spun out of the College of Washington a decade in the past as NanoSurface Biomedical. In April, Curi Bio celebrated the opening of its new 13,942-square-foot headquarters and analysis facility on the Seattle waterfront.
Keep forward of the curve with NextBusiness 24. Discover extra tales, subscribe to our e-newsletter, and be part of our rising neighborhood at nextbusiness24.com
